Mixed Covid-19 vaccines trial to be expanded to include two further jabs

14 April 2021, 00:04

A study looking at whether the Oxford/Astrazeneca and Pfizer coronavirus vaccines can be safely mixed is being expanded to other jabs
A study looking at whether the Oxford/Astrazeneca and Pfizer coronavirus vaccines can be safely mixed is being expanded to other jabs. Picture: PA

By Maddie Goodfellow

A study looking at whether the Oxford/Astrazeneca and Pfizer coronavirus vaccines can be safely mixed for the first and second doses will be expanded to include two additional jabs.

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the first two jabs to be rolled out across the UK, have announced the programme will be extended to include the Moderna and Novavax vaccines.

Led by the University of Oxford, the extra study will seek to recruit adults aged over 50 who have received their first vaccination in the past eight to 12 weeks.

Matthew Snape, associate professor in paediatrics and vaccinology at the University of Oxford, who is chief investigator on the trial said: "The focus of both this and the original Com-Cov study is to explore whether the multiple Covid-19 vaccines that are available can be used more flexibly, with different vaccines being used for the first and second dose.

"If we can show that these mixed schedules generate an immune response that is as good as the standard schedules, and without a significant increase in the vaccine reactions, this will potentially allow more people to complete their Covid-19 immunisation course more rapidly.

"This would also create resilience within the system in the event of a shortfall in availability of any of the vaccines in use."

READ MORE: Boris Johnson insists there is 'no reason' to change lockdown roadmap

READ MORE: Covid: Third wave fears as 'one million most vulnerable still unvaccinated'

Prof Gabriel Scally warns Covid is still 'really dangerous'

The volunteers, who will have received either the Oxford/AstraZeneca or Pfizer/BioNTech vaccine, will be randomly allocated to receive either the same vaccine for their second dose, or a dose of the jabs produced by Moderna or Novavax.

The Moderna jab has started being rolled out across the UK, and the Novavax jab manufactured by GlaxoSmithKline (GSK) is under rolling review by the Medicines and Healthcare products Regulatory Agency (MHRA).

The six new arms of the trial will each recruit 175 candidates, adding 1,050 recruits into this programme.

The researchers will study any adverse reactions and the immune system responses to these new combinations of vaccines.

READ MORE: Next phase of UK Covid vaccinations to begin after all over-45s offered dose

READ MORE: Moderna Covid vaccine to be rolled out in England today

Deputy head calls for pubs to remain closed until summer holidays

The study is designed as a so-called non-inferiority study, which means its intent is to demonstrate that mixing is not substantially worse than not mixing.

It will compare the immune system responses to the gold-standard responses reported in previous clinical trials of each vaccine.

If the study shows promising results, the MHRA and Joint Committee on Vaccination and Immunisation would formally assess the safety and efficacy of any new vaccination regimen before it is rolled out to patients.

Brexit voter wishes UK remained in EU despite vaccine rollout

Prof Snape said he hoped the results of the second part of the study would be available in June or July, with the first part expected to report results next month.

He told a press briefing: "What I'm hoping is that we won't rule out any combinations.

"That's how we need to look at it - are there any combinations we shouldn't be giving, because they don't generate a good immune response and I'm hoping that won't be the case.

"And that will give us lots of flexibility, not just in the UK, not just in Europe where we're looking about restricting uses of some vaccines for some age groups, but across the world, where we have, perhaps, a little bit more intermittent supply of vaccines, not as reliable.

"But let's hope that we can actually use this to get two doses of vaccine to as many people as possible."

The study is being run across nine National Institute for Health Research-supported sites by the National Immunisation Schedule Evaluation Consortium, and backed through funding from the Vaccines Taskforce and the Coalition for Epidemic Preparedness Innovations.

Professor Jeremy Brown, a member of the Joint Committee on Vaccination and Immunisation, said people will eventually "have to" mix Covid-19 jabs.

He said: "It's practically going to have to be that way because, once you've completed a course of, say, the Moderna or Pfizer or the AstraZeneca with two doses, in the future it's going to be quite difficult to guarantee you get the same type of vaccine again.

"So there will be a mix-and-match occurring just by the sort of practicalities of doing a third or fourth vaccination over the next few years...

"Getting data on that is important so there are trials at the moment about the immunological responses to the mixed-vaccine combinations."

More Latest News

See more More Latest News

Live
US Presidential Election 2024 LIVE: Millions of Americans head to the polls as election day arrives

US Presidential Election 2024 LIVE: Millions of Americans head to the polls in the final race for the White House

Proud Boys claim they will go to voting places as Trump repeats election fraud lies.

Proud Boys making plans to mobilise as Trump repeats election fraud lies

File photo of a real NHS dentist

Desperate Brits fall for scam 'fake NHS dentists' amid years-long waits for appointments

The Kremlin is suspected of plotting the attack

'Parcel bombs' that blew up in warehouse were 'rehearsal' for Russian explosion attack on flight to US

Keir Starmer is not set to ban smoking in pub gardens, contrary to earlier reports

Cigarettes will not be banned in pub gardens under new Labour plan create 'smoke-free generation'

Former President Donald Trump speaks at a campaign rally in Reading, Pennsylvania

Trump threatens Mexico with 100% tariffs unless it cracks down on border crossings

Bridget Phillipson told Tonight with Andrew Marr that the fee hike was necessary to secure the future of universities.

‘Universities must reform’ says education secretary after first hike in tuition fees in 8 years

Two more cases of a new strain of mpox have been detected in the UK, officials say

Two more cases of new mpox strain detected in UK

Anya Taylor-Joy and her musician husband were the victims of a terrifying robbery

Anya Taylor-Joy and musician husband victims of burglary at London mansion

Exclusive
Nigel Farage speaking to LBC's Nick Ferrari about new Tory leader Kemi Badenoch

'The Remainers are back in town': Nigel Farage says Kemi Badenoch will bring 'no change whatsoever' to Tories

Amy Dowden

Strictly Come Dancing star Amy Dowden will not return to show this year following 'medical emergency'

Scott Paterson murdered his landlady Annette Smith

Tenant murdered and dismembered elderly landlady before posing as her by sending Christmas cards to family

Robert Jenrick, Priti Patel and Mel Stride will all serve in Kemi Badenoch's Shadow Cabinet

Kemi Badenoch names former leadership rivals Robert Jenrick and Priti Patel to Tory Shadow Cabinet team

Bridget Phillipson has confirmed the tuition fee rise

University tuition fees to rise for first time in eight years, as Tories accuse Labour of 'declaring war on students'

Sara Sharif had suffered dozens of injuries in the weeks leading up to her death, a court has heard

Video of Sara Sharif smiling and dancing 'days before murder' shown to court

Transport for London (TfL) has warned passengers that no Tube services are expected on Thursday 7 November

November Tube strikes to bring London to a halt this week despite RMT calling off action